From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005.

Slides:



Advertisements
Similar presentations
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Advertisements

Date of download: 6/2/2016 From: Internet-Based Self-management Plus Education Compared With Usual Care in Asthma: A Randomized Trial Ann Intern Med. 2009;151(2):
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Chest Pain Relief by Nitroglycerin Does Not Predict Active Coronary Artery Disease Ann Intern Med. 2003;139(12):
Date of download: 6/3/2016 From: Surgery Versus Nonsurgical Treatment of Lumbar Spinal Stenosis: A Randomized Trial Ann Intern Med. 2015;162(7):
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
Date of download: 6/22/2016 From: Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced.
Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.
Date of download: 6/29/2016 From: Predicting Future Functional Status for Seriously Ill Hospitalized Adults: The SUPPORT Prognostic Model Ann Intern Med.
Date of download: 7/6/2016 From: Can Inexpensive Signs Encourage the Use of Stairs? Results from a Community Intervention Ann Intern Med. 1998;129(5):
Date of download: 7/9/2016 From: Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II Ann Intern.
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Development of Antidrug Antibodies Against Adalimumab.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Use of Pattern Analysis to Predict Differential Relapse.
Date of download: 9/20/2016 From: Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer: A Randomized Trial Ann.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Date of download: 11/12/2016 From: Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseA Randomized,
From: Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease Ann Intern Med. 1997;126(11):
From: Screening for Syphilis Infection in Pregnancy: U. S
Ann Intern Med. 2010;153(7): doi: / Figure Legend:
Ann Intern Med. 2016;165(7): doi: /M Figure Legend:
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
From: Effects of Pulmonary Rehabilitation on Physiologic and Psychosocial Outcomes in Patients with Chronic Obstructive Pulmonary Disease Ann Intern Med.
From: Conceptual and Technical Challenges in Network Meta-analysis
From: Perioperative Use of Dobutamine in Cardiac Surgery and Adverse Cardiac Outcome:Propensity-adjusted Analyses Anesthes. 2008;108(6): doi: /ALN.0b013e f.
From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.
From: Effects of Low-Carbohydrate and Low-Fat DietsA Randomized Trial
Ann Intern Med. 2016;164(8): doi: /M Figure Legend:
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
From: Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled TreatmentA Randomized Trial Ann Intern Med.
Ann Intern Med. 2005;143(6): doi: / Figure Legend: Flow of evidence.
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
From: Pharmacologic Therapy for Type 2 Diabetes Mellitus
From: Wells Rule and d-Dimer Testing to Rule Out Pulmonary EmbolismA Systematic Review and Individual-Patient Data Meta-analysis Ann Intern Med. 2016;165(4):
Copyright © 2004 American Medical Association. All rights reserved.
Ann Intern Med. 2000;133(6): doi: / Figure Legend:
Copyright © 2000 American Medical Association. All rights reserved.
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
Ann Intern Med. 1995;123(2): doi: / Figure Legend:
From: An Externally Validated Model for Predicting Long-Term Survival after Exercise Treadmill Testing in Patients with Suspected Coronary Artery Disease.
From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /
From: The Evolving Diabetes Burden in the United States
From: Long-Term Outcome of Anti–Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression Ann Intern Med. 2001;134(11):
From: The In-Training Examination in Internal Medicine: An Analysis of Resident Performance over Time Ann Intern Med. 2002;137(6): doi: /
Ann Intern Med. 2009;150(11): doi: / Figure Legend:
From: Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1A Randomized Trial Ann Intern Med. 2011;154(7):
From: Meta-Analysis: Pharmacologic Treatment of Obesity
Ann Intern Med. 2012;157(7): doi: / Figure Legend:
Ann Intern Med. 2011;155(8): doi: / Figure Legend:
From: Treatment of Refractory Whipple Disease with Interferon-γ
Ann Intern Med. 2008;149(1): doi: / Figure Legend:
From: Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy
From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized.
From: Reduction of Verbal Pain Scores after Anterior Cruciate Ligament Reconstruction with 2-Day Continuous Femoral Nerve Block:A Randomized Clinical Trial.
From: Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
Copyright © 2003 American Medical Association. All rights reserved.
From: Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
Copyright © 2007 American Medical Association. All rights reserved.
From: A 10-Year Experience with Universal Health Insurance in Taiwan: Measuring Changes in Health and Health Disparity Ann Intern Med. 2008;148(4):
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
From: Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia Ann Intern Med. 2012;156(11):
From: Diagnostic Accuracy of an “Amended” Insulin–Glucose Ratio for the Biochemical Diagnosis of Insulinomas Ann Intern Med. 2012;157(11): doi: /
From: Exercise Tomographic Thallium-201 Imaging in Patients with Severe Coronary Artery Disease and Normal Electrocardiograms Ann Intern Med. 1994;121(11):
Figure Legend: From: The resolution of facial expressions of emotion
From: Self-Measured Blood Pressure Monitoring in the Management of HypertensionA Systematic Review and Meta-analysis Ann Intern Med. 2013;159(3):
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
From: Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment ProgramA Randomized Trial Ann Intern Med.
Volume 53, Issue 5, Pages (May 1998)
Presentation transcript:

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: The fourth clinical visit was the first point at which a patient could meet the study definition of sustained remission (SR) (a Birmingham Vasculitis Activity Score for Wegener granulomatosis [BVAS/WG] of 0 for 6 months) and was the first time we looked for an increase in proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) levels. We compared the net absorbance of PR3-ANCA at this visit with that of the previous 2 visits or the previous 6 months (curved lines). The same comparison was done at every subsequent visit. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: Arrowheads indicate a decrease in proteinase 3 (PR3)–ANCA levels during the initial 6 months of follow-up, and circles indicate an increase in PR3-ANCA level. The horizontal line at 0.1 represents the cutoff value of the tests; results above or equal to this value are considered positive. A. Increase in PR3-ANCA levels followed by relapse (R). The increase in PR3-ANCA levels began before the patient met the definition for sustained remission (SR). B. Increase in PR3-ANCA levels with no subsequent relapse in the following 2 years. C. Relapse without a preceding increase in mature- or pro-PR3–ANCA levels. D. Unchanging PR3-ANCA levels during follow-up after sustained remission. This patient achieved and remained in sustained remission. E. Continued disease activity with a decrease in PR3-ANCA levels, although with improvement as PR3-ANCA levels decreased. F. Continuously negative PR3-ANCA levels without achieving sustained remission. BVAS/WG = Birmingham Vasculitis Activity Score for Wegener granulomatosis. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: Mature- and pro-PR3–ANCA levels were statistically significantly higher at baseline (median Birmingham Vasculitis Activity Score for Wegener granulomatosis [BVAS/WG], 6.5) than at sustained remission (BVAS/WG, 0). The median level decreased from 1.46 to 0.92 for mature-PR3 ANCA and from 0.88 to 0.40 for pro-PR3–ANCA. In this analysis, only the 101 patients who were positive for mature-PR3–ANCA at baseline and had sustained remission were included. The middle horizontal lines represent the median, and the bars represent the interquartile range. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: Top. Mature proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) levels and remission. Bottom. Pro-PR3–ANCA levels and remission. Data are Kaplan–Meier estimates of time to sustained remission in the 134 patients who were positive for mature-PR3–ANCA at baseline. Time 0 corresponds to the date of enrollment in the study. Sustained remission was defined as a Birmingham Vasculitis Activity Score (BVAS/WG) of 0 for a minimum of 6 months. Adjusting variables were age, sex, disease severity (severe vs. limited), treatment group (etanercept vs. placebo), disease duration, baseline BVAS/WG, and clinical center. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: *The increase in PR3-ANCA levels took place at or after the patient achieved sustained remission. †Fourteen of these patients had gaps in PR3-ANCA measurements longer than 6 months; of those, 4 had relapse. ‡Seventeen of these patients had gaps in PR3-ANCA measurements longer than 6 months; of those, 4 had relapse. §Seven of these patients had gaps in PR3-ANCA measurements longer than 6 months; of those, 1 had relapse. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

From: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med. 2007;147(9):611-619. doi:10.7326/0003-4819-147-9-200711060-00005 Figure Legend: The vertical dotted line marks the time of sustained remission. The x-axis corresponds to the 6 months preceding and the time following sustained remission. In patients with relapse (top), the mature-PR3–ANCA levels for each patient were plotted to the time of relapse. In patients without relapse (bottom), the mature-PR3–ANCA levels for each patient were plotted to the end of the trial. Date of download: 12/31/2017 Copyright © American College of Physicians. All rights reserved.

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.